{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-154347","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2023-05-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.609064+00:00","generated_at":"2026-06-14T14:49:04.934253+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cullinan reports Phase 1 CLN-619 data: 1 CR, 2 PRs in solid tumors; expansion in endometrial/cervical cancers","bullets":["CLN-619 monotherapy showed 1 complete response (parotid gland cancer) and 2 unconfirmed partial responses (endometrial cancer) in heavily pre-treated patients.","54% of patients had prior checkpoint inhibitor therapy; responses observed in patients who progressed on prior CPI.","No dose-limiting toxicities across 0.1-10 mg/kg doses; infusion reactions Grade 1/2 only with pre-medication.","Based on gynecologic activity, company will initiate monotherapy expansion cohorts in endometrial and cervical cancers.","Phase 1 trial continues enrolling monotherapy and combination (with pembrolizumab) arms; future results to be shared."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-154347","json":"https://secwatch.observer/filing/0001193125-23-154347.json","markdown":"https://secwatch.observer/filing/0001193125-23-154347.md","text":"https://secwatch.observer/filing/0001193125-23-154347.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312523154347/0001193125-23-154347-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312523154347/d462773d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T14:49:04.934253+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}